Steven M Grauer
Overview
Explore the profile of Steven M Grauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adams G, Pall P, Grauer S, Zhou X, Ballard J, Vavrek M, et al.
J Med Chem
. 2021 Dec;
65(1):485-496.
PMID: 34931831
Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels . The article describes the design...
2.
Grauer S, Sanoja R, Poulin D, Rashid H, Jochnowitz N, Calhoun M, et al.
Brain Res
. 2020 Apr;
1737:146814.
PMID: 32234514
Analgesic properties of orthosteric agonists of the muscarinic M receptor subtype have been documented in literature reports, with evidence from pharmacological and in vivo receptor knock out (KO) studies. Constitutive...
3.
Grauer S, Hodgson R, Hyde L
Psychopharmacology (Berl)
. 2013 Oct;
231(7):1325-37.
PMID: 24150248
Rationale: Psychoses are debilitating side effects associated with current dopaminergic treatments for Parkinson's disease (PD). Prepulse inhibition (PPI), in which a non-startling stimulus reduces startle response to a subsequent startle-eliciting...
4.
Marquis K, Comery T, Jow F, Navarra R, Grauer S, Pulicicchio C, et al.
Psychopharmacology (Berl)
. 2011 Jun;
218(4):635-47.
PMID: 21643676
Rationale: α7 nicotinic acetylcholine receptor (nAChR) agonists are proposed as candidate agents for the adjunctive treatment of cognitive deficits associated with schizophrenia. Despite the pursuit of such an approach clinically,...
5.
Childers Jr W, Havran L, Asselin M, Bicksler J, Chong D, Grosu G, et al.
J Med Chem
. 2010 May;
53(10):4066-84.
PMID: 20443629
As part of an effort to identify 5-HT(1A) antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a...
6.
Kelly M, Logue S, Brennan J, Day J, Lakkaraju S, Jiang L, et al.
Proc Natl Acad Sci U S A
. 2010 Apr;
107(18):8457-62.
PMID: 20404172
Phosphodiesterase 11A (PDE11A) is the most recently identified family of phosphodiesterases (PDEs), the only known enzymes to break down cyclic nucleotides. The tissue expression profile of this dual specificity PDE...
7.
Brennan J, Graf R, Grauer S, Navarra R, Pulicicchio C, Hughes Z, et al.
J Pharmacol Exp Ther
. 2009 Oct;
332(1):190-201.
PMID: 19828876
The preclinical characterization of WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one] is described. In vitro binding and functional studies revealed highest affinity to the D(2) receptor (D(2L) K(i), 4.0 nM) and serotonin transporter (K(i), 7.1...
8.
Logue S, Grauer S, Paulsen J, Graf R, Taylor N, Sung M, et al.
Mol Cell Neurosci
. 2009 Oct;
42(4):438-47.
PMID: 19796684
In rodents, the orphan G protein-coupled receptor, Gpr88, is highly expressed in brain regions implicated in the pathophysiology of and is modulated by treatments for schizophrenia. We compared striatal function...
9.
Rotella D, McFarlane G, Greenfield A, Grosanu C, Robichaud A, Aldrin Denny R, et al.
Bioorg Med Chem Lett
. 2009 Sep;
19(19):5552-5.
PMID: 19720528
A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules...
10.
Grauer S, Pulito V, Navarra R, Kelly M, Kelley C, Graf R, et al.
J Pharmacol Exp Ther
. 2009 Aug;
331(2):574-90.
PMID: 19661377
Following several recent reports that suggest that dual cAMP and cGMP phosphodiesterase 10A (PDE10A) inhibitors may present a novel mechanism to treat positive symptoms of schizophrenia, we sought to extend...